We propose to include damaging CYP51A1 variants in genetic testing to increase the discovery of underlying causes for diseases such as pediatric cataract neonatal hepatic failure, global developmental delay, azole susceptibility, and cardiovascular and metabolic diseases. The gene discussed is CYP51A1; the disease is Hepatic failure.